War­ring with ex-CEO, op­tions shrink­ing, Aeter­na Zen­taris turns to a strate­gic re­view

Af­ter jet­ti­son­ing its failed lead ther­a­py and con­fronting its ex-CEO and gen­er­al coun­sel with al­le­ga­tions that they were try­ing to slip them­selves the old, lead failed ther­a­py, Aeter­na Zen­taris $AEZS says it’s time to en­gage in a strate­gic re­view.

Among the op­tions on the ta­ble are re­view­ing the biotech’s busi­ness strat­e­gy as well as man­age­ment and the board.

Per­haps dis­heart­en­ing to in­vestors who have stuck with the Charleston, SC –based com­pa­ny through thick and thin, the re­lease out Tues­day af­ter­noon mis­spelled Macrilen, their on­ly as­set of any val­ue.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.